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Abstract
Background: Trastuzumab, used to treat breast cancer overexpressing human epidermal 
growth factor receptor 2, may be cardiotoxic. Cardiac magnetic resonance (CMR) imaging 
with myocardial strain studies has been used to evaluate subclinical biventricular myocardial 
changes, however, its clinical utility during chemotherapy has not been evaluated.
Methods: The clinical outcomes, CMR and cardiac biomarkers of 9 women aged 62.3 ± 12.6 
years with early or locally advanced breast cancer were evaluated at baseline, and at 3, 6 and 
12 months after the initiation of trastuzumab.
Results: None of the patients developed heart failure or elevated serum cardiac biomarkers. 
Global left ventricular (LV) peak systolic longitudinal and circumferential strains were signifi-
cantly decreased at 6 months (longitudinal strains, –21.1 ± 1.7% [baseline] vs. –19.5 ± 1.0% 
[6 months], p = 0.039, and circumferential strains, –23.4 ± 1.8% [baseline] vs. –21.6 ± 2.5% 
[6 months], p = 0.036). These changes were analogous to those observed in the LV ejection 
fraction. Right ventricular (RV) free wall peak systolic circumferential strains were decreased 
at 6 months (–20.9% ± 2.4% [baseline] vs. –19.1% ± 2.3% [6 months], p = 0.049), whereas 
RV longitudinal strains and ejection fraction remained unchanged. The LV longitudinal strain 
was the most reproducible of the 4 peak strain parameters.
Conclusions: The LV longitudinal and circumferential strains measured by CMR decreased 
during trastuzumab therapy, although their predictive value for later heart failure or associa-
tion with RV parameters was not determined. These techniques may be a useful means of di-
agnosing and monitoring trastuzumab-related cardiotoxicity. (Cardiol J 2016; 23, 3: 270–280)
Key words: cardiac magnetic resonance, myocardial strain, trastuzumab,  
breast cancer, cardiotoxicity
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Introduction
Trastuzumab, a humanized monoclonal anti-
body against the extracellular domain of human 
epidermal growth factor receptor 2 (HER2), im-
proves clinical outcomes in patients with breast 
cancer overexpressing HER2. Adjuvant therapy 
using trastuzumab reportedly reduces the risk 
of relapse by about a half and the risk of death by 
a third; a substantial body of evidence for its ben-
efits has led to trastuzumab becoming a first line 
treatment for early-stage HER2-positive breast 
cancer [1, 2].
Although generally well tolerated, trastu-
zumab is cardiotoxic in 2–27% of patients; the 
incidence varies according to the definition used 
and concomitant chemotherapy [1, 3]. The Cardiac 
Review and Evaluation Committee (CREC) that 
examined trastuzumab-associated cardiotoxic-
ity defined cardiotoxicity as a ≥ 5% reduction 
in left ventricular (LV) ejection fraction (LVEF) 
to < 55% in symptomatic patients, or a ≥ 10% 
reduction in LVEF to < 55% in asymptomatic 
patients [4]. Nevertheless, LVEF measured by 
echocardiography may not be sufficiently specific 
or sensitive to detect cardiotoxicity reliably [5, 6]. 
Deformation parameters such as myocardial strain 
have been used to detect subclinical myocardial 
dysfunction before reduced LVEF is identifiable 
on echocardiography in patients with breast cancer 
receiving trastuzumab [6–9].
Cardiac magnetic resonance (CMR) imaging 
provides excellent images of the heart, allowing 
3-dimensional assessments of LVEF and ven-
tricular volumetric function [10]. Although its high 
cost and lack of availability precludes its routine 
clinical use, CMR has been validated for serial 
monitoring of LVEF and volume in patients with 
breast cancer receiving trastuzumab, as well as for 
the characterization of myocardial tissue changes 
[7, 11, 12]. Recently, CMR has been also used to moni- 
tor right ventricular (RV) ejection fraction (RVEF) 
in cardiotoxicity [13]. Additionally, CMR can now 
be used to measure deformation parameters in 
conjugation with strain-encoded imaging (SENC) 
[14], in which objective color-coded biventricular 
longitudinal and circumferential myocardial strain 
patterns are obtained in several heartbeats and 
breath-holds.
We hypothesized that CMR-based measure-
ment of myocardial strains, in addition to the 
conventional biventricular CMR parameters, may 
be a reliable means of assessing change in cardiac 
function during chemotherapy. Our pilot study 
aimed to establish whether CMR with myocardial 
strain studies might have clinical utility in patients 
with breast cancer treated with trastuzumab.
Methods
Patient selection and study design
Of patients newly diagnosed with HER2-over-
expressing breast cancer between April 2012 and 
October 2014 in our institute, 16 women consented 
to participate in our pilot study. The exclusion 
criteria were: 1) artificial pacemaker implantation, 
2) chronic arrhythmia such as atrial fibrillation, 
3) chronic kidney disease (estimated glomeru-
lar filtration rate < 30 mL/min/1.73 m2), and 
4) metastatic cancer. Intravenous trastuzumab was 
administered at a loading dose of 8 mg/kg followed 
by 6 mg/kg every 3 weeks (a total of 18 doses) in all 
patients. Physical examination, echocardiography, 
CMR and blood tests were performed before the in-
itiation of trastuzumab, and 3 months (± 6 weeks), 
6 months (± 6 weeks) and 12 months (± 8 weeks) 
afterwards. Cardiac function was evaluated by CMR 
at each of the 4 time points, and the relationships 
with echocardiographic parameters, biomarkers 
and clinical indices were evaluated.
Data collected at baseline
Patients’ demographic characteristics, includ-
ing age and body mass index, were recorded at 
baseline. The cardiovascular history was taken 
and risk factors, including hypertension, dyslipi-
demia, diabetes mellitus, chronic atrial fibrillation, 
chronic kidney disease, coronary artery disease 
(myocardial infarction or angina pectoris) and cur-
rent smoking were assessed (see Supplementary 
Materials). Cancer-related variables, including 
side of the breast cancer, stage (early or locally 
advanced), surgical treatment, radiotherapy, and 
other concomitant chemotherapy were recorded. 
Vital signs, including systolic and diastolic blood 
pressure, and heart rate at rest were recorded. 
Echocardiographic variables, including LV end-
diastolic dimension, end-systolic dimension, and 
intra-ventricular septum and LV posterior wall 
thickness were measured, and the presence of 
significant valvular disease was evaluated. LVEF 
was calculated using the Teichholz and modified 
Simpson’s methods [15, 16].
Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging was 
performed within 28 days of echocardiography 
using a 3.0 Tesla MR imaging scanner (Archieva 
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3.0T TX, Philips Medical Systems, Best, The 
Netherlands) with a 32-element phased-array 
cardiac coil. Cine studies using steady-state free 
precession sequence in the LV vertical long-axis, 
4-chamber view, and sequential short-axis slices 
from the mitral valve to the apical levels were ob-
tained at 4 time points (Supplementary Table S1). 
T2-weighted short tau inversion recovery (STIR) 
and late-gadolinium enhancement (LGE) images 
after intravenous administration of 0.15 mmol/kg 
meglumine gadoterate (Magnescope; Guerbet 
Japan, Tokyo, Japan) were obtained at base-
line only, to exclude pre-existing cardiac dis-
ease or irreversible myocardial injury that had 
developed after previous chemotherapy. LV 
end-diastolic volume index (LVEDVI in mL/m2  
indexed by body surface area), LV end-systolic 
volume index (LVESVI in mL/m2) and LV mass 
index (LVMI in g/m2) were measured as previously 
described [17] using a Philips Extended MR Work-
space 2.6.3.4 (Philips Medical Systems). Briefly, 
using the stack of short-axis cine images, the most 
basal and apical slices of the LV were determined, 
and LV endocardial and epicardial borders were 
manually traced to obtain LVEDVI, LVESVI and 
LVMI. LVEF was calculated using the blood volume 
method, which excluded portions of papillary and 
trabecular muscle. Using the same images, RV 
end-diastolic volume index (RVEDVI in mL/m2) and 
RV end-systolic volume index (RVESVI in mL/m2) 
were measured [18]; RVEF was calculated using 
the blood volume method.
Myocardial strains were evaluated using SENC-
CMR (version 3.0; Diagnosoft, Palo Alto, CA, Fig. 1), 
based on the acquisition of two images of differing 
frequency modulation; superposition of low- and 
high-tuning images allowed a SENC strain map to 
be plotted, which was overlaid pixel-by-pixel on the 
anatomical images [14, 19]. In contrast with conven-
tional tagging, in SENC-CMR the gradient is applied 
in the slice selection direction [14], therefore, the 
short-axis view shows longitudinal myocardial strain 
and the 4-chamber view shows circumferential 
strain. Areas of myocardium with severely impaired 
or absent strain are shown in white, and areas of 
myocardium with normal strain are shown in red. 
LV longitudinal strain was measured at the basal, 
middle, and apical levels of the short-axis view; 
a region of interest was plotted in the myocardial 
middle-layer of each myocardial segment and the 
minimum value during systole (i.e., peak systolic 
strain) was recorded. Using the same images, RV 
longitudinal and circumferential strains were meas-
ured in regions of interest plotted in the RV free wall 
using a method modified from a previous report [20]. 
Global strain was defined as the mean peak systolic 
strain of all allocated segments (16 segments for 
LV longitudinal strain, 6 for circumferential strain, 
Figure 1. Measurement of peak systolic strain. Myocardial strain was measured using strain-encoded cardiac magnetic 
resonance imaging (SENC-CMR). The short-axis view shows longitudinal myocardial strain and the 4-chamber view 
shows circumferential strain. Areas of myocardium with severely impaired or absent strain are shown in white, and 
areas of myocardium with normal strain are shown in red. Global strain was defined as the mean of peak systolic strain 
of all allocated segments; A–C. Longitudinal strain, in the basal, middle and apical levels; D. Circumferential strain.
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7 segments for RV free wall longitudinal strain, and 
3 for circumferential strain). Left ventricular wall 
motion at baseline was evaluated by the agreement 
of two observers using a 17-segment model [21]. 
The detailed CMR protocol is described in Supple-
mentary Table S1.
Other data collected
Clinical signs and symptoms of heart failure 
(such as dyspnea and peripheral edema), and the 
serum concentrations of troponin-I (Architect 
STAT Troponin-I assay, Abbott Diagnostics, 
Illinois, USA), ventricular myosin light chain (SRL, 
Tokyo, Japan), and plasma B-type natriuretic pep-
tide (BNP) (TOSOH, Osaka, Japan) were measured 
at the same intervals (see Supplementary Mate-
rials). Values below the lower limit of detection 
were treated as zero. LVEF was also measured by 
echocardiography at each time point.
Statistical analysis
Continuous data are expressed as the mean 
± standard deviation (SD) and categorical data as 
the number (proportion). Independent continuous 
variables at the 3 different time points (3, 6 and 
12 months) were compared with the baseline data using 
the paired t-test. Intra- and inter-observer variability 
was evaluated for reproducibility using Pearson’s 
correlation analysis; standardized dispersion was 
expressed as coefficient of variation. Inter-modality 
comparison between CMR and echocardiography 
was also evaluated using Pearson’s correlation 
analysis. A p value < 0.05 was considered statisti-
cally significant. All analyses were performed using 
JMP V.10.0.0 (SAS Institute Inc., Cary, NC).
Ethics approval
The study was conducted according to the 
Declaration of Helsinki and approved by the Insti-
tutional Review Board of the International Medical 
Centre of Saitama Medical University, Japan (refer-
ence number 11-067).
Results
Baseline characteristics, and changes  
in echocardiographic findings and cardiac 
biomarkers from baseline
Of the 16 women enrolled, 7 were exclud-
ed as they did not undergo CMR at each of the 
4 time points due to: progression of cancer (n = 2); 
interruption by surgery (n = 3), and withdrawal 
of consent to participate (n = 2). The data of re-
maining 9 patients were analyzed. The mean age 
of the patients was 62.3 ± 12.6 years (Table 1). 
Two had essential hypertension (1 was treated 
with an angiotensin converting enzyme inhibitor), 
1 had diabetes mellitus and 1 had dyslipidemia, 
but none had previous or co-existing heart failure. 
Eight (88.9%) patients had a right-sided tumor, 
and 8 (88.9%) underwent either partial or total 
mastectomy. Intravenous epirubicin was adminis-
tered prior to trastuzumab in 6 (66.7%) patients, 
with a cumulative dose of 360 mg/m2 in 5 patients 
and 342 mg/m2 in 1 patient (in whom the dose was 
reduced owing to inflammation of the throat). Echo-
cardiography at baseline demonstrated preserved 
LVEF (71.8% ± 7.4%, range: 62.7–86.2%) and 
the absence of significant valvular disease in all 
patients. The serum concentrations of troponin I, 
myosin light chain, and plasma BNP were not 
elevated at baseline.
Throughout the observation period, none of 
the patients developed symptoms of heart failure, 
nor did any exhibit an LVEF < 55% measured by 
echocardiography (Supplementary Table S2). In all 
patients, the serum concentrations of troponin I 
and myosin light chain remained within their nor-
mal ranges, and the plasma concentration of BNP 
remained lower than £ 100 pg/mL, the validated 
cutoff value for suspected acute heart failure [22]. 
In 1 patient, borderline LVEF reduction was treated 
with an oral b-blocker, but this was discontinued 
almost immediately because of faintness.
Change in CMR parameters
There was no evidence of myocardial LGE 
or high signal intensity in T2-weighted short tau 
inversion recovery images, or abnormal LV motion 
at baseline in any of the participants. The mean 
LVESVI increased 3 months after the initiation of 
trastuzumab and remained high until 12 months. 
The LVEF (68.4 ± 6.6%, range 57.3–80.8% at ba-
seline) significantly decreased by 6 months (61.7 ± 
± 8.7%, p = 0.004 compared with baseline), and 
remained low at 12 months (62.9 ± 7.8%, p = 0.002 
compared with baseline). Over the 12-month study 
period, minimum LVEF measured by CMR fell to 
54.3% and 53.9% in 2 cases, but the corresponding 
LVEF measured by echocardiography was 61.9% and 
55.9%, respectively. Other ventricular parameters 
such as the LVEDVI and LVMI remained unchanged 
throughout the observation period. The conven-
tional RV parameters, such as RVEDVI, RVESVI, 
and RVEF remained unchanged (Fig. 2).
Global LV peak systolic longitudinal and cir-
cumferential strains significantly decreased by 
6 months (longitudinal strain, –21.1 ± 1.7% at 
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baseline vs. –19.5 ± 1.0% at 6 months, p = 0.039; 
circumferential strains, –23.4 ± 1.8% at baseline 
vs. –21.6 ± 2.5% at 6 months, p = 0.036). RV 
free wall peak systolic circumferential strains had 
decreased by 6 months (–20.9 ± 2.4% at baseline 
vs. –19.1 ± 2.3% at 6 months, p = 0.049), while 
longitudinal strain remained unchanged (Fig. 2; 
Supplementary Table S3). Images demonstrating 
a typical reduction in LV longitudinal strain are 
shown in Figure 3.
The intra-observer (measured by Dr. Nakano) 
and inter-observer (measured by Drs. Nakano and 
Tanno) correlation coefficients, and the coefficient 
of variation are shown in Table 2. The correlation 
coefficients between the LVEF measured by CMR 
and that by echocardiography using the modified 
Simpson method (26 of 36 studies), and CMR and 
echocardiography using the Teichholz method were 
0.58 (p = 0.004) and 0.46 (p = 0.004), respectively 
(Supplementary Fig. S1).
Discussion
Although the number of patients was limited, 
our pilot study is the first to have used CMR-based 
myocardial strain studies to undertake serial evalu-
ations of cardiac function in a cohort of patients 
with breast cancer treated with trastuzumab.
We found that global LV peak systolic lon-
gitudinal and circumferential strains had signifi-
cantly decreased by 6 months before recovering by 
12 months. These changes were analogous to those 
of LVEF measured by CMR. LV longitudinal strain 
was most reproducible among the 4 peak strain 
parameters. We also found that RV free wall lon-
gitudinal strain remained unchanged, whereas 
circumferential strain decreased 6 months after 
the initiation of trastuzumab. The RV circumfer-
ential strain was, however, the least reproducible 
and the coefficient of variation was the greatest of 
the 4 ventricular peak systolic strain parameters.
Role of conventional CMR in the assessment 
of chemotherapy-related cardiotoxicity
Cardiac magnetic resonance imaging has 
recently been used to characterize myocardial tis-
sue by LGE for patients with breast cancer being 
treated with chemotherapy [7, 23], as the pres-
ence of LGE may reflect irreversible myocardial 
injury [24]. In our study, no patient showed LGE at 
baseline, suggesting that no advanced myocardial 
damage had been induced by prior exposure to 
epirubicin. The mechanism of trastuzumab-related 
cardiotoxicity is unclear; it may be attributable to 
Table 1. Baseline characteristics (total: n = 9).
Demographics
Age [years] 62.3 ± 12.6 
Body mass index [kg/m2] 22.1 ± 3.4 
Cardiovascular history and risk factors
Hypertension 2 (22.2%)
Diabetes mellitus 1 (11.1%)
Dyslipidemia 1 (11.1%)
Chronic atrial fibrillation 0 (0.0%)
Chronic kidney disease 0 (0.0%)
Coronary artery disease 0 (0.0%)
Current smoking 0 (0.0%)
Cancer-related variables
Breast cancer side:  
Right 8 (88.9%)
Bilateral 0 (0.0%)
Stage: 0 (0.0%)
Early 3 (37.5%)
Locally advanced 5 (62.5%)
Metastatic 0 (0.0%)
Surgery:
Partial mastectomy + Sn 3 (33.3%)
Partial mastectomy + Ax 0 (0.0%)
Total mastectomy + Sn 2 (22.2%)
Total mastectomy + Ax 3 (33.3%)
Radiotherapy 5 (55.6%)
Other chemotherapy:
Epirubicin 6 (66.7%)
Docetaxel 3 (33.3%)
Cyclophosphamide 8 (88.9%)
Carboplatin 1 (11.1%)
Vital signs at baseline
Systolic BP [mm Hg] 125.6 ± 9.2
Diastolic BP [mm Hg] 79.4 ± 9.2
Heart rate [bpm] 77.8 ± 7.9
Echocardiographic parameters at baseline
LV end-diastolic dimension [mm] 43.2 ± 2.9
LV end-systolic dimension [mm] 25.3 ± 2.7
LV ejection fraction [%] 71.8 ± 7.4
Intra-ventricular septum thickness [mm] 9.5 ± 1.1
LV posterior wall thickness [mm] 9.3 ± 0.9
Significant valvular disease 0 (0.0%)
Cardiac biomarkers at baseline
Troponin-I [ng/mL] 0.02 ± 0.00
Myosin light chain [ng/mL] 1.33 ± 0.41
B-type natriuretic peptide [pg/mL] 23.1 ± 13.5
Continuous variables are described as the mean ± standard devia-
tion and categorical variables as number (proportion); Ax — axillary 
clearance; BP — blood pressure; LV — left ventricular; Sn — sentinel 
lymph node biopsy
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blockade of the HER2 in cardiomyocytes, repre-
senting largely reversible type II cardiotoxicity 
without ultrastructural abnormalities [2, 25]. None 
of the participants in our study exhibited progres-
sive cardiac dysfunction. Still, the technique may be 
a useful means of evaluating irreversible myocar-
dial injury in patients receiving trastuzumab follow-
ing anthracycline, as prior anthracycline exposure 
is reportedly a risk factor for trastuzumab-related 
cardiotoxicity alongside concomitant radiation 
therapy and general cardiovascular risk factors 
(such as older age, obesity, smoking, dyslipidemia, 
hypertension, diabetes mellitus and history of 
coronary artery disease) [3, 26, 27].
In our cohort of patients with breast cancer, 
the LVEF measured by CMR tended to decrease 
at 3 months, and had significantly decreased by 
6 months after the initiation of trastuzumab. This 
finding is consistent with previous studies, which 
found the reduction in LVEF was first detectable 
at approximately 3 months and reached its peak 
between 6 and 9 months after the initiation of tras-
tuzumab [7]. Although there is presently a limited 
role for the routine use of CMR in the evaluation 
of trastuzumab-related cardiotoxicity, it has several 
advantages over echocardiography, such as higher 
reproducibility and sensitivity [28]. Indeed, a sub-
stantial proportion of our echocardiographic studies 
(10 of 36, 27.8%) were of insufficient visual quality 
for data acquisition using the modified Simpson’s 
method; therefore, only the Teichholz method 
was available in all studies. Moreover, the ability 
to obtain high-quality, 3-dimensional images with 
CMR may be particularly advantageous with breast 
cancer patients with left-sided disease, because 
the mass effect of cancer or scar tissue wound may 
further obscure echocardiographic views or a pain-
ful surgical wound may interfere with the proper 
placement of the ultrasound probe. Our study 
demonstrated a modest intra-modality discrepancy 
between LVEF measured by echocardiography and 
that by CMR, which was consistent with previous 
reports [12, 29, 30]. This inherent intra-modality 
discrepancy may be important in patients with bor-
derline cardiotoxicity. In our study, neither of the 
2 patients with minimum LVEF < 55% measured 
by CMR (54.3% and 53.9% each) would have met 
the CREC criteria for cardiotoxicity if only echocar-
Figure 2. Cardiac magnetic resonance (CMR) imaging parameters. Variables at the three different time points (3, 6 and 
12 months) were compared with the baseline data using the paired t-test. Peak systolic myocardial strains are ex-
pressed as absolute values; *p < 0.05 vs. baseline; LVEDVI — left ventricular end-diastolic volume index; LVESVI — 
left ventricular end-systolic volume index; LVMI — left ventricular mass index; LV-LS — left ventricular longitudi-
nal strain; LV-CS — left ventricular circumferential strain; LVEF — left ventricular ejection fraction; RVEF — right 
ventricular ejection fraction; RVEDVI — right ventricular end-diastolic volume index; RVESVI — right ventricular 
end-systolic volume index; RV-LS — right ventricular longitudinal strain; RV-CS — right ventricular circumferential strain; 
BSL — baseline; M — months.
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Table 2. Reproducibility of peak systolic myocardial strain measured by strain-encoded cardiac  
magnetic resonance imaging.
Intra-observer variability Inter-observer variability Coefficient of variation
LV, longitudinal 0.968 0.939 –7.20%
LV, circumferential 0.926 0.871 –10.34%
RV, longitudinal 0.931 0.797 –5.94%
RV, circumferential 0.905 0.757 –12.17% 
Intra- and inter-observer variability was evaluated using Pearson’s correlation; LV — left ventricle; RV — right ventricle
Figure 3. Representative changes in left ventricular longitudinal strain (LV-LS). A 60-year-old woman previously 
treated with epirubicin demonstrated reduction in global LV-LS at 6 months (–22.4% to –18.9%) concomitant with 
a decrease in left ventricular ejection fraction (LVEF). A. Baseline: basal level; B. Baseline: middle level; C. Six month: 
basal level; D. Six month: middle level.
diography had been used to measure LVEF (61.9% 
and 55.9%, respectively).
Role of myocardial strain in the assessment 
of chemotherapy-related cardiotoxicity
Myocardial strain measured by echocardiogra-
phy has been used to detect subclinical myocardial 
dysfunction in patients with breast cancer receiving 
chemotherapy [6–9]. Fallah-Rad et al. [7] reported 
that the global LV longitudinal and radial peak 
systolic strains decreased at 3 months, followed by 
a reduction in LVEF at 6 months in those who de-
veloped trastuzumab-related cardiotoxicity. Ho et 
al. [9] reported that the global LV longitudinal peak 
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systolic strain was lower in asymptomatic breast 
cancer patients receiving anthracycline than in 
controls, even though the LVEF was broadly com-
parable between the two groups. Negishi et al. [6] 
proposed that changes in global LV longitudinal 
peak systolic strain could predict later reduction 
in LVEF in patients receiving trastuzumab, when 
taken into account alongside established clinical 
predictors. We found that CMR-based global LV 
peak systolic longitudinal and circumferential 
strains were slightly reduced at 3 months, followed 
by significant reductions at 6 months, suggesting 
that CMR-based myocardial strain studies may be 
effective means of detecting asymptomatic early 
trastuzumab-related cardiotoxicity. Specifically, 
the global LV longitudinal peak systolic strain, 
which closely reflects LV dysfunction [31], was the 
most reproducible parameter with a relatively low 
coefficient of variation, underlining its potential for 
the detection of subtle alterations in myocardial 
function attributable to trastuzumab. Changes in 
LV peak systolic strain were analogous to those 
in LVEF measured by CMR, but the predictive 
value of strain parameters for later LV dysfunction 
could not be determined. Our cohort included only 
asymptomatic patients whose LV function did not 
markedly decline during the observation period.
The RV free wall circumferential strain had 
also decreased by 6 months, but a firm conclusion 
about RV function cannot be drawn owing to the 
relatively low reproducibility of the test and the 
limited number of patients. The importance of RV 
function in predicting outcome in heart failure has 
been established [32]. Grover et al. [13] reported 
that RVEF decreased during anthracycline and/or 
trastuzumab therapy, and emphasized the impor-
tance of assessment of biventricular function in 
cardiotoxicity. Using our method, comprehensive 
evaluation of the RV parameters including myocar-
dial strains may further illuminate the mechanisms 
of trastuzumab-related cardiotoxicity.
Limitations of the study
Our study has several limitations. First, the 
cohort was small, because only those consent-
ing to participate in our study and not any other 
potentially conflicting study could be enrolled. 
However, the use of CMR-based strain studies in 
trastuzumab-related cardiomyopathy is novel and 
our findings are sufficient to suggest that CMR 
could have a role to play in routine clinical prac-
tice. Second, the strain parameters measured by 
CMR and echocardiography were not compared 
owing to the poor acoustic echocardiographic 
window in some patients; the relative merits 
of each technique are controversial and require 
further study [30]. Because the measurement of 
myocardial strains using echocardiography requires 
an adequate acoustic window, we did not compare 
strains measured by echocardiography with those 
measured by CMR. In our opinion, the limitations 
of echocardiography make a strong case for the 
use of CMR.
Conclusions
We describe the use of CMR-based biven-
tricular myocardial strain studies for the serial 
evaluation of cardiac function in patients with 
early or locally advanced breast cancer receiving 
trastuzumab. Global LV peak systolic longitudi-
nal and circumferential strains had significantly 
decreased by 6 months before recovering by 
12 months; these changes were analogous to those in 
LVEF measured by CMR. RV parameters remained 
unchanged except for a marginal decrease in peak 
systolic circumferential strains.
Cardiac magnetic resonance imaging-based 
assessment of myocardial strain thus appears to 
be a useful means of detecting cardiotoxicity in 
patients receiving trastuzumab.
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Definition of data collection at baseline
Hypertension was defined as current or previ-
ous treatment with anti-hypertensive medication. 
Diabetes mellitus was defined as current or previ-
ous treatment with antidiabetic medication (insulin 
or oral hypoglycemic drugs) or a hemoglobin A1c 
concentration of ≥ 6.5% [S1]. Dyslipidemia was 
defined as current or previous treatment with 
anti-dyslipidemic medication, a fasting serum 
low-density lipoprotein cholesterol concentration 
≥ 160 mg/dL, high-density lipoprotein cholesterol 
concentration £ 40 mg/dL, or total cholesterol 
concentration ≥ 240 mg/dL [S2].
Normal values of biomarkers
Lower limit of detection levels and upper limit of 
normal values were 0.02–0.30 ng/mL for troponin I, 
1.0–2.50 ng/mL for myosin light chain, and 4.0–18.40 
pg/mL for B-type natriuretic peptide. Values below 
the lower limit of detection were treated as zero.
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Supplementary Table S1. Detailed cardiac magnetic resonance protocol.
Study Repetition  
time [ms]
Echo time 
[ms]
Flip angle  
[°]
Pixel area 
[mm]
Voxel size* 
[mm]
Slice thickness 
[mm]
Inter-slice gap 
[mm]
Cine 2.8 1.42 50 2.97 × 1.69 0.74 × 0.74 8 2
T2 STIR 2000 70 90 1.48 × 1.97 0.74 × 0.74 10 –
LGE 3.1 1.49 15 1.48 × 1.90 0.74 × 0.74 3 –
SENC 25 0.88 30 3.0 × 3.0 1.0 × 1.0 10 –
*Reconstruction voxel size; STIR — short tau inversion recovery; LGE — late-gadolinium enhancement; SENC — strain-encoded imaging
Supplementary Table S2. Echocardiographic parameters at each time point.
Baseline 3 months P 6 months P 12 months P
LV end-diastolic dimension [mm] 43.2 ± 2.9 45.6 ± 1.9 0.069 45.3 ± 3.0 0.084 45.0 ± 2.8 0.088
LV end-systolic dimension [mm] 25.8 ± 1.8 28.1 ± 3.4 0.072 28.1 ± 2.9 0.072 28.5 ± 2.2 0.001*
LV ejection fraction [%] 70.8 ± 5.6 68.7 ± 7.1 0.362 68.9 ± 6.0 0.037* 66.4 ± 5.9 0.113
Intra-ventricular wall thickness [mm] 9.5 ± 1.1 9.0 ± 1.3 0.252 9.4 ± 0.7 0.701 9.0 ± 1.3 0.369
LV posterior wall thickness [mm] 9.3 ± 0.9 9.4 ± 1.3 0.767 9.6 ± 1.7 0.270 8.9 ± 1.3 0.463
Continuous variables are reported as the mean ± standard deviation; *P < 0.05 vs. baseline; LV — left ventricle
SUPPLEMENTARY MATERIALS 
Detailed definition of data at baseline
280 www.cardiologyjournal.org
Cardiology Journal 2016, Vol. 23, No. 3
Supplementary Figure S1. Linear regression plots comparing left-ventricular ejection fraction (LVEF) measured by 
cardiac magnetic resonance (CMR) and echocardiography; A. Modified Simpson method; B. Teichholz method; 
Pearson’s correlation analysis.
Supplementary Table S3. Cardiac magnetic resonance parameters at each time point.
Baseline 3 months P 6 months P 12 months P
Conventional parameters
LV end-diastolic volume index [mL/m2] 56.8 ± 7.5 59.7 ± 7.0 0.114 58.4 ± 3.7 0.424 59.0 ± 7.8 0.425
LV end-systolic volume index [mL/m2] 24.8 ± 6.7 28.4 ± 7.2 0.024* 30.7 ± 5.4 0.004* 30.5 ± 5.7 0.002*
LV ejection fraction [%] 68.4 ± 6.6 65.4 ± 8.7 0.176 61.7 ± 8.7 0.004* 62.9 ± 7.8 0.017*
LV wall mass index [g/m2] 23.4 ± 4.7 22.9 ± 4.3 0.761 25.2 ± 4.3 0.343 23.2 ± 5.1 0.934
RV end-diastolic volume index [mL/m2] 68.7 ± 16.3 72.4 ± 15.0 0.256 72.0 ± 12.3 0.443 73.0 ± 14.9 0.204
RV end-systolic volume index [mL/m2] 46.0 ± 13.8 46.8 ± 13.2 0.780 47.2 ± 11.8 0.703 46.5 ± 11.6 0.876
RV ejection fraction [%] 30.7 ± 9.0 31.3 ± 8.5 0.888 31.4 ± 7.3 0.880 31.0 ± 7.4 0.814
Peak systolic strain
Global LV, longitudinal [%] –21.1 ± 1.7 –20.1 ± 1.5 0.128 –19.5 ± 1.0 0.039* –20.7 ± 1.2 0.622
Global LV, circumferential [%] –23.4 ± 1.8 –21.9 ± 2.7 0.124 –21.6 ± 2.5 0.036* –21.8 ± 2.3 0.080
RV free wall, longitudinal [%] –23.3 ± 1.3 –22.6 ± 1.2 0.168 –22.3 ± 1.5 0.096 –22.7 ± 1.7 0.384
RV free wall, circumferential [%] –20.9 ± 2.4 –21.2 ± 2.4 0.749 –19.1 ± 2.3 0.049* –20.0 ± 1.6 0.276
Continuous variables are reported as the mean ± standard deviation; *P < 0.05 vs. baseline; LV — left ventricle; RV — right ventricle
